Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Antengene Awarded Orphan Status for Claudin 18.2 ADC in Two Cancer Indications

publication date: May 23, 2023

Shanghai Antengene announced the US FDA awarded two Orphan Drug Designations for ATG-022, a Claudin 18.2 antibody drug conjugate, one for gastric cancer and another for pancreatic cancer. Claudins are cell adhesion molecules normally expressed between cells to form a barrier that regulates cell permeability. In cancer, Claudins are expressed on the cell surface due to changes in cell polarity. The Claudin 18.2 isoform is overexpressed in gastric, esophageal and pancreatic cancers. ATG-022 has started Phase I trials in China and Australia. More details....

Stock Symbol: (HK: 6996)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital